관련문헌 등
1)Harrison's Principles of Internal Medicine, 21e (2022)
2)Williams Textbook of Endocrinology, 15e (2025)
3)DeGroot's Endocrinology, 8e (2023)
4)Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14e (2023)
5)The Pituitary, 5e (2022)
6)Consensus on Diagnosis and Management of Cushing‘s Disease: A Guideline Update (2021)
7)Update in Cushing disease: What the neurosurgeon has to KNOW, on behalf of the EANS skull base section (2022)
8)Clinical Guidelines for the Diagnosis and Treatment of Cushing’s Disease in Korea (2015)
9)R.Pivonello et al. Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase Disease. Lancet Diabetes Endocrinal 2020; 8: pages 748-61.
10)R. Pivonello et al. Improvement in clinical features of hypercortisolism during osilodrostat treatment: findings from the Phase III LINC 3 trial in Cushing's disease. Journal of Endocrinological Investigation (2024) 47:pages 2437？2448
11)Gadelha M et al. Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. The Journal of Clinical Endocrinology & Metabolism, 2022, 107, e2882？e2895
11)Fleseriu et al. Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension. European Journal of Ednocrinology(2022) 187, 521-541.
12)Gadelha M et al. Long-term efficacy and safety of osilodrostat in patients with Cushing’s disease: results from the LINC 4 study extension. Frontiers in Endocrinology, 2023;14:1236465.
13)Shimatsu et al. Osilodrostat treatment in patients with Cushing’s disease of Asian or non-Asian origin: a pooled analysis of two Phase Ⅲ randomized trials (LINC 3 and LINC 4). Endocr J, 2024;71(12):1103-1123.
14)대한내과학회(대내학 2025-043호, 2025.1.16.)
15)대한내분비학회(대내학 제2025-8호, 2025.1.16.)
16)대한신경외과학회(25-보험-006, 2025.1.16.)
17)PBAC(2024.9.)
18)HAS(2021.5.)